Purchase this article with an account.
Thomas S. Shute, Ursula M. Dietrich, Julia F. M. Baker, K. Paige Carmichael, William Wustenberg, Iqbal Ike K. Ahmed, Arsham Sheybani; Biocompatibility of a Novel Microfistula Implant in Nonprimate Mammals for the Surgical Treatment of Glaucoma. Invest. Ophthalmol. Vis. Sci. 2016;57(8):3594-3600. doi: https://doi.org/10.1167/iovs.16-19453.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
The purpose of this study was to evaluate the ocular safety of a novel microfistula implant and its composite materials in an animal model.
The anterior chambers of 12 rabbit eyes were injected with either glutaraldehyde cross-linked porcine gelatin extract or balanced salt solution and were followed by serial slit lamp examinations over 3 days. The eyes of 18 canines underwent microfistula implantation or a sham procedure. The animals were monitored over the subsequent 12 months, using serial slit lamp examinations, indirect ophthalmoscopy, tonometry, specular microscopy, and high-resolution ultrasonography. Ocular tissues were examined histopathologically on postoperative days 7, 30, 90, 180, and 365.
Glutaraldehyde cross-linked porcine gelatin did not induce significant intraocular inflammation in the rabbit model. The microfistula implant was well tolerated and did not stimulate significant tissue response in the canine eye. The microfistula tube did not undergo structural change or degradation over the course of the study.
In nonprimate mammals, the material composing the microfistula implant and the implant itself do not induce significant inflammation or tissue reaction.
This PDF is available to Subscribers Only